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Role of angiotensin in renal vascular development. All compo-
nents of the renin-angiotensin system (RAS) are expressed in the
developing kidney in a temporospatial pattern that suggests a role
for this system in kidney morphogenesis. Pharmacological block-
ade of angiotensin actions in fetal and newborn animals results in
striking alterations in kidney architecture, including immature
glomeruli and papillae, dilated tubuli, and arrested vascular
development. Inactivation of angiotensinogen or angiotensin con-
verting enzyme genes in mice results in similar anomalies that
begin as subtle alterations in early life and become more pro-
nounced as extrauterine life progresses. However, inactivation of
each angiotensin receptor subtype does not result in obvious
morphological abnormalities, suggesting functional redundancy at
the receptor level. Crossing of mice lacking the various receptor
subtypes should be revealing. Overall, the available information
suggests that the RAS is necessary for the normal morphological
and functional development of the kidney and the preservation of
kidney architecture in adult life.
The definitive mammalian kidney, the metanephros,
results from coinductive interaction between the primitive
ureter and the metanephric blastema. The differentiating
ureter arising from the mesonephric (Wolffian) duct in-
duces the transformation of the metanephric mesenchyma
into tubular and glomerular epithelium [1]. In turn, the
induced mesenchyma stimulates the ureter to continue to
differentiate and branch within the renal mesenchyma. As
the ureter branches, the mesenchymal cells condense
around each ureteric tip. The condensate develops into a
vesicle, followed by a comma-shaped body. The creation of
a lower cleft into the latter structure results in the forma-
tion of the S-shaped glomerulus. The formation of the
S-shaped glomerulus seems to be critical for glomerular
vascularization, because at this stage, endothelial cell pre-
cursors invade the lower cleft and form the glomerular
capillaries. At this stage, proximal and distal tubules can be
distinguished readily. Further tubular and glomerular
growth results in the formation of a nephron with adult
characteristics. In humans, nephrogenesis starts around the
fifth week of gestation and culminates around weeks 32 to
36. Thus, full-term infants are born with a full complement
of nephrons. In mice and rats, the metanephros is visible
around the embryonic (E) days 11 to 12 and 13 to 14 (term:
21 to 22 days), respectively, and continues in postnatal life.
Thus, the neonatal mice and rat kidneys are useful models
to study extrauterine nephrogenesis.
VASCULAR DEVELOPMENT
Precise and timely assembly of the kidney vasculature in
concert with the developing nephron is fundamental for the
development of a kidney capable of sustaining indepen-
dent, extrauterine life. Kidney vascularization and nephro-
genesis are simultaneous and coordinated processes [2].
The embryonic origin and mechanism underlying blood
vessel formation in the kidney are still under debate.
Endothelial cells may differentiate in situ from local mes-
enchymal cell precursors (vasculogenesis), or they may
originate and sprout from pre-existing extrarenal or intra-
renal vessel (angiogenesis) and migrate into the developing
nephron [3, 4]. Both paradigms are not mutually exclusive
and are supported by available experimental evidence.
Precursors for smooth muscle, endothelial, and renin-
expressing cells are present in the embryonic rat kidney
well before vessel formation can be detected [5–7]. These
precursor cells have the potential to differentiate and
participate in the assembly of the arteriolar vessel wall.
Once the arteriolar vessels are formed, the anatomical
arrangement of the kidney vasculature is as follows: In the
rat, a single renal artery divides at the level of the hilum
into three main lobar arteries. Each lobar artery is contin-
ued by corticomedullary (arcuate) arteries that course
through the corticomedullary junction parallel to the kid-
ney cortex. From the arcuate arteries, numerous cortico-
radial (interlobular) arteries originate that in turn give off
the afferent arterioles of the glomeruli. As expected, this
basic blueprint of arteriolar development is already estab-
lished in the fetal rat by E20. As maturation continues, the
arterial tree grows in complexity and surface area. This is
achieved mainly by a progressive and continued increase in
the number of small arterial branches, especially interlob-
ular arteries and afferent arterioles [7]. In fact, in the
developing rat, arteriolar branching is very rapid up to day
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10 postnatum (P10), while nephrogenesis is still occurring.
The mechanisms that control arteriolar branching are not
well understood and currently are being investigated. As
discussed later here, components of the renin-angiotensin
system (RAS) seem to play a role in this process.
RAS AND VASCULAR DEVELOPMENT IN THE
KIDNEY
All the components of the RAS are expressed in the
developing kidney [8]. In the rat metanephros, renin-
expressing cells are found as early as day E14, before vessel
or nephron formation has taken place. At E19, these cells
are found along arcuate and interlobular arteries [9, 10]. As
the kidney continues its development through fetal and
postnatal life, renin distribution shifts from the larger
arteries in the fetus to its mature juxtaglomerular localiza-
tion in the adult animal [9]. These developmental patterns
of renin expression have been observed in every species
examined thus far [8]. In addition, we have recently ob-
served an association between renin-expressing cells and
branching of renal arterioles, suggesting a role for these
cells in renal angiogenesis [10]. Angiotensinogen (Atg), the
only known precursor of angiotensin (Ang) peptides, is
detected in the fetal rat kidney by E17 to E18 [8, 11, 12].
However, the renal expression of Atg is highest around the
time of birth. In newborn rats, Atg is expressed in proximal
tubules, mesangial cells, and vascular bundles. Ang-con-
verting enzyme (ACE) is seen in endothelial precursors
invading the lower cleft of the S-shaped body, in glomerular
capillaries, corticomedullary arteries, proximal tubules, and
peritubular capillaries [13, 14]. In addition to ACE, other
proteases are capable of generating Ang in the developing
kidney [15]. The high expression of components of the RAS
in the developing kidney is reflected functionally by its
higher levels of ANG compared with the adult rat kidney
[15]. ANG receptors are also expressed in the maturing
kidney in a characteristic developmental pattern [16, 17]. In
the rat, both Ang receptor subtypes (AT1 and AT2) are
expressed throughout metanephric development, albeit in
differing temporal and spatial patterns (Fig. 1). At E14,
when the ureteric bud is beginning to branch and nephrons
and vessels have not yet been formed, AT2 receptors are
more abundant and are present in the undifferentiated
metanephric blastema. AT1 receptors are also present in
the mesenchyma, although in lesser numbers (Fig. 1).
At E17, nephrogenesis and vascularization are both
occurring actively. A sagittal section of the kidney at this
stage shows numerous glomeruli and arterioles at various
stages of maturation, with the more mature glomeruli
localized deeper within the cortex. At this stage, AT1
Fig. 1. Expression of angiotensin receptor
subtypes AT1 and AT2 during nephrogenesis.
AT1 is represented by the hatched areas and
AT2 by the gray areas. The density of pattern
indicates the intensity of expression. (A)
Embryonic day 14 (E14) metanephros showing
intense expression of AT2 (right side) and
sparse expression of AT1 throughout the renal
mesenchyma. (B) E15 to E20 metanephros
showing persistence of AT2 in mesenchyma and
termination in epithelial structures while AT1
expression increases in more mature nephrons.
(C) Postnatal days 7 to 15 showing the gradient
of maturing nephrons. AT2 predominates in the
differentiating areas, whereas AT1
predominates in more mature juxtamedullary
nephrons. (D) Adult kidney showing the
persistence of AT1 in mature glomeruli and
tubules. AT2 is not detectable at this stage.
Taken from [16] with permission from the
American Society of Physiology.
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receptors are found in the more mature glomeruli, whereas
AT2 receptors are present in condensed mesenchyme and
(transiently) in newly formed nephrons (Fig. 1). At E20, the
kidney architecture is better defined, showing distinct med-
ullary and cortical regions; there is still an outer nephro-
genic zone. AT1 and AT2 are equally prevalent within the
outer medullary stripe, the more developed glomeruli,
large arteries, and the medullary rays. AT2 is abundant in
the medullary rays, the nephrogenic cortex, and the col-
umns of Bertin. After birth, AT1 predominates in more
mature juxtamedullary nephrons, and AT2 continues to be
expressed in differentiating structures. As nephron matu-
ration is achieved, AT2 expression is down-regulated until
it disappears after the second postnatal week (Fig. 1). In
contrast, as nephrons differentiate, AT1 expression in-
creases and becomes maximal around the first postnatal
week. By the end of 1 month of postnatal life, AT1
expression is similar to that of the adult (Fig. 1). The
pattern of receptor expression shown previously here has
been documented in several animal species, suggesting
unique and perhaps opposite functions of the two recep-
tors. Overall, the expression pattern of RAS components
during ontogeny suggests a role for this system in kidney
development, as discussed later here.
Blockade of the AT1 receptor in newborn rats up to P12
results in striking alterations in the developing kidney
architecture [18]. In addition to a reduced number of
immature glomeruli and dilated tubules, the renal arte-
rioles are thick, short, and markedly reduced in numbers.
Papillary atrophy that correlates functionally with a de-
creased urinary concentrating capacity and inability to
excrete an acute volume load properly is found also [19,
20]. Interestingly, these functional abnormalities persist
into adulthood, even if the treatment is stopped after P23.
Pigs treated neonatally with ACE inhibitors develop similar
morphological and functional abnormalities [21]. Fetal
anuria and renal abnormalities have also been described in
humans treated with ACE inhibitors [22]. More severe
renal-vascular abnormalities have also been noted in frog
tadpoles receiving ACE inhibitors during their metamor-
phosis [18], suggesting that the mesonephric kidney of frogs
is more susceptible to blockers of the RAS. Contrary to the
findings with ACE and AT1 inhibitors, treatment of neo-
natal animals with AT2 blockers does not seem to induce
any developmental abnormalities in vivo. Treatment of
weaning rats with losartan does not induce renal abnormal-
ities [23]. These findings suggest that the developing rat
kidney is susceptible to RAS blockade mainly during the
last five days of pregnancy and during the first two to three
postnatal weeks [24]. As discussed earlier here, this period
is associated with high expression of renin, Atg, and AT1
receptors. Presumably, the human kidney is more suscep-
tible to the deleterious effects of RAS blockers during the
last weeks of pregnancy.
Contrary to the results obtained with pharmacological
inhibitors of the RAS, targeted inactivation of each of the
AT1 receptors (AT1A, AT1B) and AT2 receptors does not
result in alterations in morphological kidney development
[25–30], suggesting that the contribution of each individual
receptor to kidney morphogenesis is limited or that it can
be compensated by the action of the other Ang receptor
subtypes. It would be interesting to determine whether
mice with inactivation of both receptor subtypes (AT1A
and AT1B) develop renal and/or vascular abnormalities.
Targeted inactivation of Atg and ACE genes, however,
produces remarkably similar renal abnormalities in adult
mice, consisting of diminished numbers of thickened, hy-
percellular renal arterioles (Fig. 2), interstitial fibrosis,
Fig. 2. Effect of deletion of the gene for
angiotensin converting enzyme (ACE) on the
renal arterial tree. Left: wild type (ACE1/1);
right knock-out (ACE2/2) mice. Both vascular
trees are stained with renin antibody (dark
brown color). The arterioles in the ACE2/2
mice are thickened and sparse compared with
the delicate arterioles in the wild-type. Renin
staining is limited to the end of afferent
arterioles in ACE1/1 but is distributed broadly
along the vascular tree in ACE2/2 mice.
Taken from [8] with permission.
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papillary atrophy, and tubular dilatation [31–33]. In both
knockout models, the abnormalities are obvious by P7 to
P10 and become more pronounced with increasing age.
There is disagreement as to whether abnormalities are seen
at earlier stages in life: Nagata et al [33] found no effect of
lack of Atg on nephrogenesis, whereas Niimura et al [32]
reported delay in glomerular maturation and smaller glo-
meruli in Atg2/2 mice. Consistent with the latter, we find
subtle alterations in interstitial architecture at E18. Arrest
in vascular and glomerular development is already obvious
by P7. These studies clearly demonstrate that both the ACE
and Atg genes are necessary for the preservation of normal
kidney structure during development and in adult life.
Whereas in rats treated with RAS blockers and in mutant
mice, there is disagreement as to whether glomerular
development is affected [18, 32, 34] or not [19, 24, 33], and
there is agreement that the renal arterioles and tubules are
most severely affected by perturbations of the RAS during
development.
The similarities of findings between Atg- and ACE-
mutant mice suggest that lack of angiotensin II is respon-
sible for the kidney pathology. It is also possible that other
Ang fragments may be involved. In either case, the identity
of the receptor(s) mediating the phenomenon is less clear
and remains to be established. In summary, the aforemen-
tioned studies indicate that the RAS is an important
regulator of renal-vascular development, a function that
seems to be conserved across the phylogenetic scale.
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APPENDIX
Abbreviations used in this article are: Ang, angiotensin; ACE, angio-
tensin converting enzyme; Atg, angiotensinogen; E, embryonic; RAS,
renin-angiotensin system.
NOTE ADDED IN PROOF
Recently, Tsuchida et al [35] reported that mice deficient in both AT1A
and AT1B receptors have kidney vascular abnormalities similar to those
found in Atg2/2 mice.
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